Member Info for Laura2022

At £650k market cap and recent private funding for French assets and new 28% holder who may fund (like happens on AYM

Thought?

And there it is

Breaking out

Thanks Pipsey

Laura2022

Posts: 14,461

Price: 0.13

No Opinion

RE: M & A Phillip Naughton TR128 Oct 2025 11:56

I would suspect they know the £5mln of assets ( conservative) are worth a lot more and Black, Cooley and Naighton have pushed Roland to one side and he's reacted petuantl

Excellent Info

Off topic NG

Huge 12mths seller finally out DIS

See huge trade

Added more FUM

AT

Will do, but risen from 6p already

I am watcjing EQT as could do an AYM

[ ] Key growth/CAGR markets which PYC operate

□MMID 18% CAGR with market set to be $13bln

□Bio Statistics 24% CAGR $40bln market

Regulatory authorities across the world require robust biometrics practices to approve new drugs. Biometrics typically incorporates three main areas:

1. Biostatistics: Supporting the design of clinical studies and analysis of resulting data

2. Statistical Programming: Use of programming language to process, analyse and visualise clinical data

3. Data Management: Setup and oversight of the collection, entry, and validation of clinical trial data

□Personalised medicine 7.5% CAGR and largest market is North America ( partner DoseMeRx based there)

Juxsta

Morning

Can't see that being filled !!

Ive done well from companies priced for bust ( WHI 400%, AYM 350% POLX 150%)

I think FUM, SBTX PYC ( all bio tech) have good chance of following

And now a 15% TR1 activist investor ?

Worth a go imho

From here ?

In auction as SETS

Major shareholders (as at 4 December 2025)

Shareholders holding more than 3% of the share capital of Futura were:

Lombard Odier Asset Management (Europe) Limited  14.17%

Cantor Fitzgerald Europe 14.15%

T Adams 6.89%

Spreadex LTD * this includes indirect and direct holding*6.72%

WT Lamb Investments Limited 4.51%

RA Lamb 3.28%

Very large long term holders

Shareholder information

Securities in issue (as at 4 December 2025)

The Company does not hold any Ordinary Shares in treasury and therefore the number of Ordinary Shares with voting rights is 581,120,659.

There are no restrictions on the transfer of Futura Medical plc shares.

Major shareholders (as at 4 December 2025)

Shareholders holding more than 3% of the share capital of Futura were:

Lombard Odier Asset Management (Europe) Limited14.17%Cantor Fitzgerald Europe14.15%T Adams6.89%Spreadex LTD                                                               * this includes indirect and direct holding*6.72%WT Lamb Investments Limited4.51%RA Lamb3.28%

ATtrades

Also large chart breakout imminent after 1.2p goes ( see 3 and 6mth)

Alex Duggan, CEO of Futura, commented: "The grant of this patent in China will mark an important milestone for Futura in one of the largest Erectile Dysfunction markets globally. We now have an enhanced competitive position which supports our commercial strategy as we actively seek partners in this market. We look forward to updating the market on progress in due course."

The prevalence of erectile dysfunction in the 700 million adult males in China is estimated to be approximately 50%, which represents a considerable commercial opportunity.

This allowance adds to the Company's existing protection in Europe, Hong Kong, Taiwan and the US, further consolidating its global IP. Other applications in additional markets remain pending. In addition, Futura Medical is planning to extend its IP protection in China by filing a divisional patent in early 2026.

Alex Duggan, CEO of Futura, commented: "The grant of this patent in China will mark an important milestone for Futura in one of the largest Erectile Dysfunction markets globally. We now have an enhanced competitive position which supports our commercial strategy as we actively seek partners in this market. We look forward to updating the market on progress in due course."

Physiomics Awarded New Contract by GARDP FOUNDATION

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract in the biometrics department with a new client, GARDP Foundation ("GARDP"). GARDP is a not-for-profit research and development organisation that addresses global public health needs by developing new or improved antibiotic treatments, while endeavouring to ensure sustainable access.

Hepran

Most of placing went to II and insiders

Cash requirement and use of proceeds

The Company believes that the net proceeds of the Fundraise will enable the Group to continue trading as a going concern and will provide scope for the Company to complete its negotiations with its US and EU licensing partners, to continue development of Eroxon Intense and WSD4000 and allow the Board to consider strategic options and explore the maximising of value for Shareholders in 2026. The Fundraise will facilitate the possibility of appointing an APAC distribution partner for Eroxon in H1 2026, with potential launch of Eroxon Intense to follow in 2027 and will enable the Board to explore in parallel the divestment or full out-licence of Eroxon and/or Eroxon Intense. The proceeds of the Fundraise will also facilitate completion of further testing of WSD4000 and negotiations with regional partners and enable the Board to explore the potential for external funding for a Phase 3 clinical trial for WSD4000.

The net proceeds of the Fundraise, combined with the Company's existing cash resources, an expected tax credit refund for the 2025 financial year, the US patent milestone payment expected to be received during H1 2026 and proceeds from ongoing sales of Eroxon, are expected to provide the Company with a cash runway to December 2026.